TABLE 3.
Treatment and outcomes to date among hospitalized patients with COVID-19
| All (n = 68) | Moderate disease (n = 41) | Severe disease (n = 27) | |
|---|---|---|---|
| Changes in immunosuppression (%)a | |||
| Decrease or hold antimetabolite | 42/48 (88) | 27/32 (84) | 15/16 (94) |
| Decreased or hold steroids | 3/43 (7) | 1/27 (4) | 2/16 (13) |
| Decrease or hold CNI | 10/56 (18) | 5/35 (14) | 5/21 (23) |
| Anti-viral treatment (%) | |||
| Hydroxychloroquine | 62 (91) | 38 (93) | 24 (89) |
| Azithromycin | 45 (66) | 26 (63) | 19 (70) |
| Remdesivir | 2 (3) | 1 (2) | 1 (4) |
| Unknown | 2 (3) | 0 (0) | 2 (7) |
| Immunomodulatory therapy (%) | |||
| Bolus steroids | 16 (24) | 6 (15) | 10 (37) |
| Tocilizumab | 14 (21) | 6 (15) | 8 (30) |
| Highest level of respiratory support (%) | |||
| Room air | 13 (19) | 13 (32) | 0 (0) |
| Nasal cannula | 20 (29) | 20 (49) | 0 (0) |
| NRB/high flow/BIPAP | 10 (12) | 6 (15) | 4 (15) |
| Intubation | 24 (35) | 0 (0) | 23 (85) |
| ECMO | 0 (0) | 0 (0) | 0 (0) |
| Unknown | 1 (1) | 1 (2) | 0 (0) |
| ICU admission (%) | 23 (34) | 0 (0) | 23 (85) |
| Mortality (%) | 16 (24) | 0 (0) | 16 (59) |
| Discharge (%) | 37 (54) | 35 (85) | 2 (7) |
| Readmission (%) | 1 (6) | 1 (2) | 0 (0) |
a
Denominator includes patients on the agent at baseline and known adjustment status.